Kyorin Holdings, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Dividend Guidance for Second Quarter and Full Year of Fiscal Year Ending March 31, 2016; Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2016
August 01, 2015 at 05:58 am
Share
KYORIN Holdings, Inc. announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of JPY 26,567 million compared with JPY 26,397 million for the same period a year ago. Operating income was JPY 2,173 million compared with JPY 3,575 million for the same period a year ago. Ordinary income was JPY 2,316 million compared with JPY 3,847 million for the same period a year ago. Net income was JPY 1,757 million or JPY 23.76 per share compared with JPY 2,681 million or JPY 35.88 per share for the same period a year ago.
The company provided dividend guidance for second quarter and full year of fiscal year ending March 31, 2016. For the quarter, the company plans to pay an interim dividend of JPY 20.00 per share against JPY 20.00 per share paid a year ago.
For the year, the company plans to pay final dividend of JPY 32.00 per share against JPY 32.00 per share paid a year ago.
The company provided earnings guidance for the first half and full year of fiscal year ending March 31, 2016. For the first half, on consolidated basis, the company expects to report net sales of JPY 54,400 million, operating income of JPY 3,800 million, ordinary income of JPY 4,000 million and profit attributable to owners of parent of JPY 2,600 million or JPY 52.20 per share.
For the full year, on consolidated basis, the company expects to report net sales of JPY 120,200 million, operating income of JPY 16,000 million, ordinary income of JPY 16,300 million and profit attributable to owners of parent of JPY 11,500 million or JPY 155.51 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Kyorin Holdings, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Dividend Guidance for Second Quarter and Full Year of Fiscal Year Ending March 31, 2016; Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2016